• Explore /
  • Poster
  • / Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).

Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).

Abstract Video & Slides Poster

Authors

null

Dingzhi Huang

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Dingzhi Huang , Diansheng Zhong , Cuiying Zhang , Yan Zhang , Yanhong Shang , Liuchun Wang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03736837

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9573)

DOI

10.1200/JCO.2020.38.15_suppl.9573

Abstract #

9573

Poster Bd #

339

Abstract Disclosures

Similar Posters

First Author: Gemma Bruera

First Author: Paul Stockhammer

First Author: Akito Hata

First Author: Jonathan N. Priantti